-
1
-
-
55249116841
-
Chromosomal translocations: Revisited yet again
-
Rowley JD. Chromosomal translocations: revisited yet again. Blood 2008; 112:2183-2189.
-
(2008)
Blood
, vol.112
, pp. 2183-2189
-
-
Rowley, J.D.1
-
3
-
-
0037114753
-
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461)
-
Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
-
(2002)
Blood
, vol.100
, pp. 4325-4336
-
-
Byrd, J.C.1
Mrozek, K.2
Dodge, R.K.3
-
4
-
-
0032188805
-
The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
-
Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322-2333.
-
(1998)
The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood
, vol.92
, pp. 2322-2333
-
-
Grimwade, D.1
Walker, H.2
Oliver, F.3
-
5
-
-
69149100639
-
Acquired copy number alterations in adult acute myeloid leukemia genomes
-
Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A 2009; 106: 12950-12955.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 12950-12955
-
-
Walter, M.J.1
Payton, J.E.2
Ries, R.E.3
-
6
-
-
76749153827
-
Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis
-
Bullinger L, Kronke J, Schon C, et al. Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia 2010; 24:438-449.
-
(2010)
Leukemia
, vol.24
, pp. 438-449
-
-
Bullinger, L.1
Kronke, J.2
Schon, C.3
-
7
-
-
36249012571
-
DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes
-
Suela J, Alvarez S, Cigudosa JC. DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes. Cytogenet Genome Res 2007; 118:304-309.
-
(2007)
Cytogenet Genome Res
, vol.118
, pp. 304-309
-
-
Suela, J.1
Alvarez, S.2
Cigudosa, J.C.3
-
8
-
-
84879352656
-
How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
-
Patel JP, Levine RL. How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia? Hematology Am Soc Hematol Educ Program 2012; 2012:28-34.
-
(2012)
Hematology Am Soc Hematol Educ Program
, vol.2012
, pp. 28-34
-
-
Patel, J.P.1
Levine, R.L.2
-
10
-
-
84863393263
-
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia
-
Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366:1079-1089.
-
(2012)
N Engl J Med
, vol.366
, pp. 1079-1089
-
-
Patel, J.P.1
Gonen, M.2
Figueroa, M.E.3
-
11
-
-
0034672269
-
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study
-
Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96:4075-4083.
-
(2000)
Blood
, vol.96
, pp. 4075-4083
-
-
Slovak, M.L.1
Kopecky, K.J.2
Cassileth, P.A.3
-
12
-
-
54349092877
-
Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype
-
Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008; 26:4791-4797.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4791-4797
-
-
Breems, D.A.1
Van Putten, W.L.2
De Greef, G.E.3
-
13
-
-
79960661181
-
Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: A GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities
-
Perrot A, Luquet I, Pigneux A, et al. Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities. Blood 2011; 118:679-685.
-
(2011)
Blood
, vol.118
, pp. 679-685
-
-
Perrot, A.1
Luquet, I.2
Pigneux, A.3
-
14
-
-
84857734093
-
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
-
Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 2012; 119:2114-2121.
-
(2012)
Blood
, vol.119
, pp. 2114-2121
-
-
Rucker, F.G.1
Schlenk, R.F.2
Bullinger, L.3
-
15
-
-
0035885955
-
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
-
Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98:1752-1759.
-
(2001)
Blood
, vol.98
, pp. 1752-1759
-
-
Kottaridis, P.D.1
Gale, R.E.2
Frew, M.E.3
-
16
-
-
0037114829
-
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm
-
Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002; 100:4372-4380.
-
(2002)
Blood
, vol.100
, pp. 4372-4380
-
-
Frohling, S.1
Schlenk, R.F.2
Breitruck, J.3
-
17
-
-
0037097716
-
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis
-
Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99:4326-4335.
-
(2002)
Blood
, vol.99
, pp. 4326-4335
-
-
Thiede, C.1
Steudel, C.2
Mohr, B.3
-
18
-
-
0036659931
-
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
-
Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100:59-66.
-
(2002)
Blood
, vol.100
, pp. 59-66
-
-
Schnittger, S.1
Schoch, C.2
Dugas, M.3
-
19
-
-
84890029517
-
Phase i study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status
-
Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 2013; 31:3681-3687.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3681-3687
-
-
Cortes, J.E.1
Kantarjian, H.2
Foran, J.M.3
-
20
-
-
33748467435
-
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): A Cancer and Leukemia Group B Study
-
Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24:3904-3911.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3904-3911
-
-
Paschka, P.1
Marcucci, G.2
Ruppert, A.S.3
-
21
-
-
77955907891
-
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication
-
Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010; 28:3636-3643.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3636-3643
-
-
Paschka, P.1
Schlenk, R.F.2
Gaidzik, V.I.3
-
22
-
-
79960534917
-
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
-
Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011; 118:409-412.
-
(2011)
Blood
, vol.118
, pp. 409-412
-
-
Green, C.L.1
Evans, C.M.2
Zhao, L.3
-
23
-
-
77449146413
-
Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome
-
Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010; 28:570-577.
-
(2010)
J Clin Oncol
, vol.28
, pp. 570-577
-
-
Dufour, A.1
Schneider, F.2
Metzeler, K.H.3
-
24
-
-
0029856349
-
Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapyinduced bone marrow aplasia
-
Wodnar-Filipowicz A, Lyman SD, Gratwohl A, et al. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapyinduced bone marrow aplasia. Blood 1996; 88:4493-4499.
-
(1996)
Blood
, vol.88
, pp. 4493-4499
-
-
Wodnar-Filipowicz, A.1
Lyman, S.D.2
Gratwohl, A.3
-
25
-
-
0036943456
-
Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy
-
Bojko P, Pawloski D, Stellberg W, et al. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy. Ann Hematol 2002; 81:522-528.
-
(2002)
Ann Hematol
, vol.81
, pp. 522-528
-
-
Bojko, P.1
Pawloski, D.2
Stellberg, W.3
-
26
-
-
84894047576
-
Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants
-
Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 2013; 122:3607-3615.
-
(2013)
Blood
, vol.122
, pp. 3607-3615
-
-
Galanis, A.1
Ma, H.2
Rajkhowa, T.3
-
27
-
-
79960058024
-
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor
-
Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20:53-65.
-
(2011)
Cancer Cell
, vol.20
, pp. 53-65
-
-
Daigle, S.R.1
Olhava, E.J.2
Therkelsen, C.A.3
-
28
-
-
84886864184
-
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
-
Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013; 122:1017-1025.
-
(2013)
Blood
, vol.122
, pp. 1017-1025
-
-
Daigle, S.R.1
Olhava, E.J.2
Therkelsen, C.A.3
-
29
-
-
84877620952
-
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
-
Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013; 340:622-626.
-
(2013)
Science
, vol.340
, pp. 622-626
-
-
Wang, F.1
Travins, J.2
Delabarre, B.3
-
30
-
-
84888265282
-
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML
-
Chaturvedi A, Araujo Cruz MM, Jyotsana N, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013; 122:2877-2887.
-
(2013)
Blood
, vol.122
, pp. 2877-2887
-
-
Chaturvedi, A.1
Araujo Cruz, M.M.2
Jyotsana, N.3
-
31
-
-
84865749132
-
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
-
Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 2012; 120:1765-1773.
-
(2012)
Blood
, vol.120
, pp. 1765-1773
-
-
Ranganathan, P.1
Yu, X.2
Na, C.3
-
32
-
-
0028084756
-
Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations
-
Caligiuri MA, Schichman SA, Strout MP, et al. Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Cancer Res 1994; 54:370-373.
-
(1994)
Cancer Res
, vol.54
, pp. 370-373
-
-
Caligiuri, M.A.1
Schichman, S.A.2
Strout, M.P.3
-
33
-
-
0030451722
-
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
-
Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10:1911-1918.
-
(1996)
Leukemia
, vol.10
, pp. 1911-1918
-
-
Nakao, M.1
Yokota, S.2
Iwai, T.3
-
34
-
-
0035476264
-
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study
-
Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 2001; 61:7233-7239.
-
(2001)
Cancer Res
, vol.61
, pp. 7233-7239
-
-
Whitman, S.P.1
Archer, K.J.2
Feng, L.3
-
35
-
-
0036682174
-
Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: A study of the Acute Myeloid Leukemia Study Group Ulm
-
Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002; 20:3254-3261.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3254-3261
-
-
Dohner, K.1
Tobis, K.2
Ulrich, R.3
-
36
-
-
0031984414
-
Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics
-
Caligiuri MA, Strout MP, Lawrence D, et al. Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 1998; 58:55-59.
-
(1998)
Cancer Res
, vol.58
, pp. 55-59
-
-
Caligiuri, M.A.1
Strout, M.P.2
Lawrence, D.3
-
37
-
-
0037108111
-
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study fromthe Acute Leukemia French Association (ALFA)
-
Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study fromthe Acute Leukemia French Association (ALFA). Blood 2002; 100:2717-2723.
-
(2002)
Blood
, vol.100
, pp. 2717-2723
-
-
Preudhomme, C.1
Sagot, C.2
Boissel, N.3
-
38
-
-
1442356729
-
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations
-
Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22:624-633.
-
(2004)
J Clin Oncol
, vol.22
, pp. 624-633
-
-
Frohling, S.1
Schlenk, R.F.2
Stolze, I.3
-
39
-
-
28444473100
-
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations
-
Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106:3740-3746.
-
(2005)
Blood
, vol.106
, pp. 3740-3746
-
-
Dohner, K.1
Schlenk, R.F.2
Habdank, M.3
-
40
-
-
28444449081
-
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
-
Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106:3733-3739.
-
(2005)
Blood
, vol.106
, pp. 3733-3739
-
-
Schnittger, S.1
Schoch, C.2
Kern, W.3
-
41
-
-
33646557337
-
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)
-
Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107:4011-4020.
-
(2006)
Blood
, vol.107
, pp. 4011-4020
-
-
Thiede, C.1
Koch, S.2
Creutzig, E.3
-
42
-
-
28444446313
-
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
-
Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106:3747-3754.
-
(2005)
Blood
, vol.106
, pp. 3747-3754
-
-
Verhaak, R.G.1
Goudswaard, C.S.2
Van Putten, W.3
-
43
-
-
42949142189
-
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
-
Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918.
-
(2008)
N Engl J Med
, vol.358
, pp. 1909-1918
-
-
Schlenk, R.F.1
Dohner, K.2
Krauter, J.3
-
44
-
-
77449159028
-
Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet
-
Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115:453-474.
-
(2010)
Blood
, vol.115
, pp. 453-474
-
-
Dohner, H.1
Estey, E.H.2
Amadori, S.3
-
45
-
-
55549101623
-
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
-
Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456:66-72.
-
(2008)
Nature
, vol.456
, pp. 66-72
-
-
Ley, T.J.1
Mardis, E.R.2
Ding, L.3
-
46
-
-
70149093912
-
Recurring mutations found by sequencing an acute myeloid leukemia genome
-
Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361:1058-1066.
-
(2009)
N Engl J Med
, vol.361
, pp. 1058-1066
-
-
Mardis, E.R.1
Ding, L.2
Dooling, D.J.3
-
47
-
-
78649906060
-
DNMT3A mutations in acute myeloid leukemia
-
Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363:2424-2433.
-
(2010)
N Engl J Med
, vol.363
, pp. 2424-2433
-
-
Ley, T.J.1
Ding, L.2
Walter, M.J.3
-
48
-
-
79953176952
-
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia
-
Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011; 43:309-315.
-
(2011)
Nat Genet
, vol.43
, pp. 309-315
-
-
Yan, X.J.1
Xu, J.2
Gu, Z.H.3
-
49
-
-
84255176496
-
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
-
Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 118:6920-6929.
-
(2011)
Blood
, vol.118
, pp. 6920-6929
-
-
Metzeler, K.H.1
Becker, H.2
Maharry, K.3
-
50
-
-
67651065502
-
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
-
Abdel-Wahab O,Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114:144-147.
-
(2009)
Blood
, vol.114
, pp. 144-147
-
-
Abdel-Wahab, O.1
Mullally, A.2
Hedvat, C.3
-
51
-
-
78650019179
-
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation
-
Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18:553-567.
-
(2010)
Cancer Cell
, vol.18
, pp. 553-567
-
-
Figueroa, M.E.1
Abdel-Wahab, O.2
Lu, C.3
-
52
-
-
84864255882
-
The origin and evolution of mutations in acute myeloid leukemia
-
Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150:264-278.
-
(2012)
Cell
, vol.150
, pp. 264-278
-
-
Welch, J.S.1
Ley, T.J.2
Link, D.C.3
-
53
-
-
43449096376
-
Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice
-
Falini B, Martelli MP, Mecucci C, et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008; 93:775-779.
-
(2008)
Haematologica
, vol.93
, pp. 775-779
-
-
Falini, B.1
Martelli, M.P.2
Mecucci, C.3
-
54
-
-
59449089329
-
Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: Evidence of NPM1 mutation stability
-
Meloni G, Mancini M, Gianfelici V, et al. Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability. Haematologica 2009; 94:298-300.
-
(2009)
Haematologica
, vol.94
, pp. 298-300
-
-
Meloni, G.1
Mancini, M.2
Gianfelici, V.3
-
55
-
-
0036786289
-
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: A comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
-
Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002; 100:2387-2392.
-
(2002)
Blood
, vol.100
, pp. 2387-2392
-
-
Shih, L.Y.1
Huang, C.F.2
Wu, J.H.3
-
56
-
-
77957192661
-
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value
-
Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 2010; 116:2122-2126.
-
(2010)
Blood
, vol.116
, pp. 2122-2126
-
-
Abbas, S.1
Lugthart, S.2
Kavelaars, F.G.3
-
57
-
-
77957286222
-
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: A study by the Acute Leukemia French Association group
-
Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2010; 28:3717-3723.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3717-3723
-
-
Boissel, N.1
Nibourel, O.2
Renneville, A.3
-
58
-
-
70350450588
-
Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: A collaborative study of the French CBF-AML intergroup
-
Prebet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol 2009; 27:4747-4753.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4747-4753
-
-
Prebet, T.1
Boissel, N.2
Reutenauer, S.3
-
59
-
-
84888219405
-
Clinical and biological implications of driver mutations in myelodysplastic syndromes
-
Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122:3616-3627.
-
(2013)
Blood
, vol.122
, pp. 3616-3627
-
-
Papaemmanuil, E.1
Gerstung, M.2
Malcovati, L.3
-
60
-
-
80052097088
-
Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia
-
Park SH, Chi HS, Min SK, et al. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011; 35:1376-1383.
-
(2011)
Leuk Res
, vol.35
, pp. 1376-1383
-
-
Park, S.H.1
Chi, H.S.2
Min, S.K.3
-
61
-
-
33646432204
-
Prognostic impact of c-KIT mutations in core binding factor leukemias: An Italian retrospective study
-
Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006; 107:3463-3468.
-
(2006)
Blood
, vol.107
, pp. 3463-3468
-
-
Cairoli, R.1
Beghini, A.2
Grillo, G.3
-
62
-
-
0038170400
-
Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
-
Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol 2003; 121:775-777.
-
(2003)
Br J Haematol
, vol.121
, pp. 775-777
-
-
Care, R.S.1
Valk, P.J.2
Goodeve, A.C.3
-
63
-
-
33744487375
-
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
-
Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006; 20:965-970.
-
(2006)
Leukemia
, vol.20
, pp. 965-970
-
-
Boissel, N.1
Leroy, H.2
Brethon, B.3
-
64
-
-
0028803283
-
Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia
-
Lyman SD, Seaberg M, Hanna R, et al. Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood 1995; 86:4091-4096.
-
(1995)
Blood
, vol.86
, pp. 4091-4096
-
-
Lyman, S.D.1
Seaberg, M.2
Hanna, R.3
-
65
-
-
77449149374
-
Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia
-
Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28:556-561.
-
(2010)
J Clin Oncol
, vol.28
, pp. 556-561
-
-
Cashen, A.F.1
Schiller, G.J.2
O'Donnell, M.R.3
Dipersio, J.F.4
-
66
-
-
77952140672
-
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
-
Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010; 107:7473-7478.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 7473-7478
-
-
Blum, W.1
Garzon, R.2
Klisovic, R.B.3
-
67
-
-
84860772157
-
DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
-
Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 2012; 26:1106-1107.
-
(2012)
Leukemia
, vol.26
, pp. 1106-1107
-
-
Metzeler, K.H.1
Walker, A.2
Geyer, S.3
-
68
-
-
79960229916
-
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
-
Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25:1147-1152.
-
(2011)
Leukemia
, vol.25
, pp. 1147-1152
-
-
Itzykson, R.1
Kosmider, O.2
Cluzeau, T.3
-
69
-
-
84881035623
-
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
-
Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013; 121:4655-4662.
-
(2013)
Blood
, vol.121
, pp. 4655-4662
-
-
Ravandi, F.1
Alattar, M.L.2
Grunwald, M.R.3
-
70
-
-
84886534519
-
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: Results from a randomized, placebo-controlled trial
-
Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013; 31:3110-3118.
-
(2013)
J Clin Oncol
, vol.31
, pp. 3110-3118
-
-
Serve, H.1
Krug, U.2
Wagner, R.3
-
71
-
-
84873569249
-
FLT3 inhibition: A moving and evolving target in acute myeloid leukaemia
-
Leung AY, Man CH, Kwong YL. FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. Leukemia 2013; 27:260-268.
-
(2013)
Leukemia
, vol.27
, pp. 260-268
-
-
Leung, A.Y.1
Man, C.H.2
Kwong, Y.L.3
-
72
-
-
80054771760
-
Treatment of FLT3-ITDpositive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib
-
Sharma M, Ravandi F, Bayraktar UD, et al. Treatment of FLT3-ITDpositive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011; 17: 1874-1877.
-
(2011)
Biol Blood Marrow Transplant
, vol.17
, pp. 1874-1877
-
-
Sharma, M.1
Ravandi, F.2
Bayraktar, U.D.3
-
73
-
-
84861906112
-
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: Favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
-
Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood 2012; 119:5133-5143.
-
(2012)
Blood
, vol.119
, pp. 5133-5143
-
-
Man, C.H.1
Fung, T.K.2
Ho, C.3
-
74
-
-
84860747223
-
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
-
Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485:260-263.
-
(2012)
Nature
, vol.485
, pp. 260-263
-
-
Smith, C.C.1
Wang, Q.2
Chin, C.S.3
-
75
-
-
84878372012
-
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia
-
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059-2074.
-
(2013)
N Engl J Med
, vol.368
, pp. 2059-2074
-
-
|